NFKB1 and neoplasm: Furthermore, downregulating LINC00886 reduces the expression of TLR4, Myd88, phosphorylated NF-κB p65, and PD-L1, while increasing TNF-α and IFN-γ levels and enhancing CD8 + T cell antitumor activity, thereby reducing tumor cell immune escape.